The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. “Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in …
Read More »Tirzepatide reduces obesity-associated breast cancer growth in mouse model
